Limitations, agreements, and source contact

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer · Source last updated 2025-10-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

ClinicalTrials.gov@lilly.com

organization

Eli Lilly and Company

phone

800-595-5979

title

Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice